AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY

Stryker Spine9 enrolled

Overview

This is a post-market clinical study of the AccuLIF expandable transforaminal lumbar interbody fusion (TLIF) cage in patients requiring surgery for degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis, at one or two levels, between L2 and S1.

Study evaluations will be evaluated pre-operatively and at 6-weeks, 3-months, 6-months, 12-months and 24-months post-operatively to assess clinical outcomes, patient reported outcomes and radiographic status.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Degenerative Disc Disease Spondylolisthesis, Grade 1 Retrolisthesis

Interventions

AccuLIF expandable TLIF cageDEVICE

AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject is skeletally mature and between 18 and 70 years of age. 2. DDD and up to Grade I spondylolisthesis or retrolisthesis, requiring decompression and arthrodesis at one or two contiguous levels between L2 and S1. 3. No previous surgery at the same or adjacent level (other than microdiscectomy / laminectomy) at the same or adjacent level. 4. Non-responsive to conservative (non-surgical) treatment for back pain for a minimum of 6 months. 5. Subject understands the conditions of enrollment and is willing to sign and date the Informed Consent. 6. Subject agrees to comply with visit schedule and completing study questionnaires. Exclusion Criteria: 1. Significant instability of the spine. 2. Requires TLIF at more than 2 levels between L2 and S1. 3. Previously undergone lumbar spine surgery (other than microdiscectomy / laminectomy) at the same or adjacent level. 4. Younger than 18 years of age, or older than 70 years of age. 5. BMI of 40 or greater. 6. History of metabolic bone disease 7. Osteoporosis 8. Diabetes mellitus requiring daily insulin management. 9. Subject has any of the following: 1. Progressive neuromuscular disease; OR 2. Autoimmune disease; OR 3. Active malignancy within the last 15 years; OR 4. Active hepatitis; OR 5. AIDS, ARC, or is HIV positive; OR 6. Syringomyelia at any spinal level; OR 7. Any other condition that would interfere with the subject self -assessment of pain, function or quality of life. 10. Allergy to implant materials (titanium, titanium alloy). 11. Active systemic infection or infection localized to the site of implantation. 12. Primary or metastatic tumors involving the spine. 13. Open wounds or inadequate issue tissue coverage over the operative site. 14. History of significant mental illness or mental incapacity. 15. Pregnancy or intent to become pregnant. 16. Participating in another investigational study for a similar purpose. 17. Belongs to a vulnerable population that would compromise ability to provide informed consent or compliance with follow-up requirements. 18. Smokers unwilling to cease up to 3 months post-op or recent history of alcohol or other substance abuse within the past 2 years. 19. Workers compensation.

Locations (1)

University of Missouri Health Care

Columbia, Missouri, United States

Outcomes

Primary Outcomes

Post-operative Radiographic Measurements to Evaluate Segmental Lordosis as Measured by Degree of Change From Pre-operative X-rays.

Post-operative radiographic measurements to evaluate segmental lordosis as measured by degree of change from pre-operative x-rays.

Time frame: 24 months

Pre-operative Comparison to Post-operative Radiographic Outcomes of Disc Height as Measured in mm.

Pre-operative comparison to post-operative radiographic outcomes of disc height as measured in mm.

Time frame: 24 months

Secondary Outcomes

Surgical Outcomes: To Measure the Length of Surgery as Measured in Time of Surgery Duration.

Surgical Outcomes: To measure the length of surgery as measured in time of surgery duration.

Time frame: Operative Visit

Surgical Outcomes: To Evaluate the Length of Time Hospitalized for the Index Procedure as Measured in Days.

Surgical Outcomes: To evaluate the length of time hospitalized for the index procedure as measured in days.

Time frame: Peri-op

Surgical Outcomes: To Measure the Amount of Blood Loss at the Time of Surgery.

Surgical Outcomes: To measure the amount of blood loss at the time of surgery.

Time frame: Operative Visit

Medical Outcomes: Incidence of Complications Associated With the Procedure and/or Device.

Medical Outcomes: Incidence of complications associated with the procedure and/or device.

Time frame: 24 months

Medical Outcomes: Comparison of Pre-operative Neurological Reflex Evaluations in the Lower Extremities to Post-operative Findings

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.